<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137358</url>
  </required_header>
  <id_info>
    <org_study_id>ETH175-04D</org_study_id>
    <nct_id>NCT00137358</nct_id>
  </id_info>
  <brief_title>Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer</brief_title>
  <official_title>Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <brief_summary>
    <textblock>
      Investigator has since decided not to pursue this protocol further. No patients were
      enrolled.

      This study is to determine the maximum tolerated dose of external beam radiation to the
      para-aortic lymph nodes using intensity modulated radiation therapy (IMRT).

      This protocol will test the hypothesis that the use of IMRT and amifostine will decrease GI
      toxicity and therefore allow the radiation dose to the para-aortic lymph nodes to be safely
      escalated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I open-label multi-institutional study that will enroll a minimum of 27 and
      up to 42 patients with locally advanced cervical cancer (a minimum of 27 will be entered if
      all dose levels are explored without reaching a dose limiting toxicity at any level). The
      primary objective is to determine the maximum tolerated dose (MTD) of external beam radiation
      to the para-aortic lymph nodes using IMRT and amifostine. Patients will be stratified
      according to gross tumor volume (GTV) prior to dose escalation.

      Within each GTV stratum, the dose escalation will be determined as follows: Accrue 3 patients
      in the first dose level based on the determined stratum. A Dose Limiting Toxicity is defined
      as the development of &gt; Grade 3 acute GI toxicity, per the RTOG acute toxicity scale. If no
      DLT is observed at the first dose level, 3 patients will be enrolled at the next dose level.
      If one patient experiences DLT at a given dose level, 3 additional patients will be enrolled
      at that dose level. If 0 of these 3 additional patients experience DLT, dosing of the next
      dose level is begun. If 1 or more of these 3 additional patients experience DLT at the
      highest dose level below the maximally administered dose, this dose becomes the recommended
      dose. At least 6 patients must be entered at this recommended dose. The Maximum Tolerated
      Dose (MTD) is defined as the dose preceding that at which 2 of 6 patients experience dose
      limiting toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    unable to obtain funding to conduct study
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to determine the maximum tolerated dose (MTD) of external beam radiation to the para-aortic lymph nodes using IMRT and amifostine.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints include local-regional control, overall survival and toxicity.</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No prior therapy other than biopsy of the cervix or endoscopic pelvic nodal resection.

          -  Patients may have endoscopic resection of enlarged pelvic and low common iliac nodes,
             however, needle biopsy only of enlarged para-aortic nodes will be eligible for entry.

          -  Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible.

          -  Patients must have no evidence of metastatic disease outside of the pelvis (except to
             the para-aortic nodes).

          -  Patients must have Zubrod performance status 0-1 and no medical contraindications to
             the administration of full dose chemotherapy.

          -  Patients must have a life expectancy &gt; 6 months

          -  Adequate bone marrow function: white blood cell (WBC) 3000/mm3 (absolute neutrophil
             count [ANC] 1500/mm3); adequate renal function: creatinine 1.5 mg/dl (urinary
             diversion is permitted to improve renal function); patients must have bilirubin 1.5
             mg/dl, ALT 2 x normal.

          -  No prior (within last 3 years) or simultaneous malignancies (other than basal cell or
             non-invasive tumors)

        Exclusion Criteria:

          -  Complete resection of the involved para-aortic nodes.

          -  Patients with evidence of bowel adherent to the GTV by contrast enhanced computed
             tomography (CT) scan will be ineligible.

          -  Patients with the following histologies will be ineligible: glassy cell, small cell,
             carcinoid, adenoid cystic, and clear cell.

          -  Prior (within last 3 years) malignancies other than basal cell carcinoma or
             non-invasive malignancies.

          -  Prior chemotherapy.

          -  Prior pelvic or abdominal radiation (other than transvaginal irradiation to control
             bleeding).

          -  Prior tumor-directed surgery other than lymph node sampling/staging

          -  Life expectancy &lt; 6 months

          -  Patients who are pregnant will be ineligible.

          -  Patients with insulin dependent diabetes will be ineligible.

          -  Patients who are obese, such that reliable immobilization is not achieved.

          -  Patients with pain or discomfort that would preclude lying still for extended periods
             of time.

          -  Patients with tumors that are bleeding and require more immediate treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer F De Los Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):982-7.</citation>
    <PMID>11704321</PMID>
  </reference>
  <reference>
    <citation>Berman ML, Keys H, Creasman W, DiSaia P, Bundy B, Blessing J. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984 Sep;19(1):8-16.</citation>
    <PMID>6469092</PMID>
  </reference>
  <reference>
    <citation>Lepanto P, Littman P, Mikuta J, Davis L, Celebre J. Treatment of para-aortic nodes in carcinoma of the cervix. Cancer. 1975 Jun;35(6):1510-3.</citation>
    <PMID>807311</PMID>
  </reference>
  <reference>
    <citation>Lovecchio JL, Averette HE, Donato D, Bell J. 5-year survival of patients with periaortic nodal metastases in clinical stage IB and IIA cervical carcinoma. Gynecol Oncol. 1989 Jul;34(1):43-5.</citation>
    <PMID>2737524</PMID>
  </reference>
  <reference>
    <citation>Nori D, Valentine E, Hilaris BS. The role of paraaortic node irradiation in the treatment of cancer of the cervix. Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1469-73.</citation>
    <PMID>4019270</PMID>
  </reference>
  <reference>
    <citation>Tewfik HH, Buchsbaum HJ, Latourette HB, Lifshitz SG, Tewfik FA. Para-aortic lymph node irradiation in carcinoma of the cervix after exploratory laparotomy and biopsy-proven positive aortic nodes. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):13-8.</citation>
    <PMID>7061247</PMID>
  </reference>
  <reference>
    <citation>Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):733-8.</citation>
    <PMID>11172956</PMID>
  </reference>
  <reference>
    <citation>Rubin SC, Brookland R, Mikuta JJ, Mangan C, Sutton G, Danoff B. Para-aortic nodal metastases in early cervical carcinoma: long-term survival following extended-field radiotherapy. Gynecol Oncol. 1984 Jun;18(2):213-7.</citation>
    <PMID>6735264</PMID>
  </reference>
  <reference>
    <citation>Carl UM, Bahnsen J, Wiegel T. Radiation therapy of para-aortic lymph nodes in cancer of the uterine cervix. Acta Oncol. 1993;32(1):63-7.</citation>
    <PMID>8466766</PMID>
  </reference>
  <reference>
    <citation>Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1015-23.</citation>
    <PMID>9869224</PMID>
  </reference>
  <reference>
    <citation>Podczaski E, Stryker JA, Kaminski P, Ndubisi B, Larson J, DeGeest K, Sorosky J, Mortel R. Extended-field radiation therapy for carcinoma of the cervix. Cancer. 1990 Jul 15;66(2):251-8.</citation>
    <PMID>2369710</PMID>
  </reference>
  <reference>
    <citation>Malfetano JH, Keys H. Aggressive multimodality treatment for cervical cancer with paraaortic lymph node metastases. Gynecol Oncol. 1991 Jul;42(1):44-7.</citation>
    <PMID>1916509</PMID>
  </reference>
  <reference>
    <citation>Mutic S, Malyapa RS, Grigsby PW, Dehdashti F, Miller TR, Zoberi I, Bosch WR, Esthappan J, Low DA. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):28-35.</citation>
    <PMID>12504033</PMID>
  </reference>
  <reference>
    <citation>Aoki T, Nagata Y, Mizowaki T, Kokubo M, Negoro Y, Takayama K, Mitsumori M, Sasai K, Hiraoka M. Clinical evaluation of dynamic arc conformal radiotherapy for paraaortic lymph node metastasis. Radiother Oncol. 2003 Apr;67(1):113-8.</citation>
    <PMID>12758247</PMID>
  </reference>
  <reference>
    <citation>Wadler S, Goldberg G, Fields A, Anderson P, Beitler JJ, Sood B, Haynes H, Runowicz C. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Semin Oncol. 1996 Aug;23(4 Suppl 8):64-8. Review.</citation>
    <PMID>8783670</PMID>
  </reference>
  <reference>
    <citation>Gallardo D, Mohar A, Calderillo G, Mota A, Solorza G, Lozano A, Solano P, De La Garza J. Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix. Int J Gynecol Cancer. 1999 May;9(3):225-230.</citation>
    <PMID>11240771</PMID>
  </reference>
  <reference>
    <citation>Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000 Jun;18(11):2226-33.</citation>
    <PMID>10829042</PMID>
  </reference>
  <reference>
    <citation>Athanassiou H, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR, Panousaki K, Karageorgis P, Throuvalas N; Oncology Hellenic Group. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1154-60.</citation>
    <PMID>12829154</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jennifer F. De Los Santos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cervical</keyword>
  <keyword>Uterine</keyword>
  <keyword>Para-aortic</keyword>
  <keyword>Nodes</keyword>
  <keyword>IMRT</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

